Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
View Patent ↗The present invention provides a method of identifying a human subject having increased or decreased sensitivity to warfarin, comprising detecting in the subject the presence of a single nucleotide polymorphism in the VKOR gene, wherein the single nucleotide polymorphism is correlated with increased or decreased sensitivity to warfarin, thereby identifying the subject having increased or decreased sensitivity to warfarin.
1. A method of amplifying a segment of a VKOR genomic nucleotide sequence, comprising:
a) choosing a first oligonucleotide primer from the 3′ end of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:8;
b) choosing a second oligonucleotide primer from the 5′ end of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:8;
c) adding said first primer and said second primer to a nucleic acid sample; and
d) amplifying a segment of the VKOR genomic nucleotide sequence defined by the first primer and the second primer, wherein said nucleic acid sample is from a subject in need of warfarin therapy.
2. The method of claim 1 , wherein the amplified segment of step (d) is less than 100 base pairs in length.
3. The method of claim 1 , wherein the amplified segment of step (d) comprises a single nucleotide polymorphism.
4. The method of claim 1 , wherein the first oligonucleotide primer is at least 15 nucleotides in length.
5. The method of claim 1 , wherein the second oligonucleotide primer is at least 15 nucleotides in length.
6. A method of amplifying a segment of a VKOR genomic nucleotide sequence, comprising:
a) choosing a first oligonucleotide primer from a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:8;
b) choosing a second oligonucleotide primer from a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:8 that differs in nucleotide sequence from the first oligonucleotide primer;
c) adding said first primer and said second primer to a nucleic acid sample; and
d) amplifying a segment of the VKOR genomic nucleotide sequence defined by the first primer and the second primer, wherein said nucleic acid sample is from a subject in need of warfarin therapy.
7. The method of claim 6 , wherein the amplified segment of step (d) is less than 100 base pairs in length.
8. The method of claim 6 , wherein the amplified segment of step (d) comprises a single nucleotide polymorphism.
9. The method of claim 6 , wherein the first oligonucleotide primer is at least 15 nucleotides in length.
10. The method of claim 6 , wherein the second oligonucleotide primer is at least 15 nucleotides in length.